Patents by Inventor Youji Hu
Youji Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8206899Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: January 21, 2011Date of Patent: June 26, 2012Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang
-
Publication number: 20110111979Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer, The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: ApplicationFiled: January 21, 2011Publication date: May 12, 2011Inventors: Mark Stearns, Youji Hu, Min Wang
-
Patent number: 7939274Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: May 18, 2010Date of Patent: May 10, 2011Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Patent number: 7790861Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: May 7, 2002Date of Patent: September 7, 2010Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang -
Publication number: 20100221753Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: ApplicationFiled: May 18, 2010Publication date: September 2, 2010Inventors: MARK STEARNS, YOUJI HU, MIN WANG
-
Publication number: 20100184843Abstract: The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.Type: ApplicationFiled: January 7, 2010Publication date: July 22, 2010Applicant: PHILADELPHIA HEALTH & EDUCATION CORPORATIONInventors: MARK E. STEARNS, YOUJI HU, MIN WANG
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Patent number: 7754435Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: November 2, 2004Date of Patent: July 13, 2010Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang -
Patent number: 7666584Abstract: The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.Type: GrantFiled: September 1, 2006Date of Patent: February 23, 2010Assignee: Philadelphia Health & Education CoporationInventors: Mark E. Stearns, Youji Hu, Min Wang
-
Publication number: 20070099214Abstract: The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.Type: ApplicationFiled: September 1, 2006Publication date: May 3, 2007Applicant: PHILADELPHIA HEALTH & EDUCATION CORPORATION d/b/a Drexel University College of MedicineInventors: Mark Stearns, Youji Hu, Min Wang
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Publication number: 20050142592Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: ApplicationFiled: November 2, 2004Publication date: June 30, 2005Inventors: Mark Stearns, Youji Hu, Min Wang -
Publication number: 20030207339Abstract: The present invention provides a cancer marker protein, PCAM-1, and polynucleotides which identify and encode this protein. Detection of this marker is useful in diagnosing and prognosticating cancer in a patient. Also provided are expression vectors and host cells for expression of PCAM-1 as well as antibodies raised against the PCAM-1 protein. In addition, a Monte Carlo-like screening assay for identification of specific 8 mer sequences which selectively bind proteins in a crude extrract of tissues, cells or other biological fluids is provided.Type: ApplicationFiled: March 15, 2002Publication date: November 6, 2003Applicant: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Publication number: 20030100033Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: ApplicationFiled: May 7, 2002Publication date: May 29, 2003Inventors: Mark Stearns, Youji Hu, Min Wang -
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Publication number: 20020042062Abstract: The invention relates to novel nucleic acids encoding a mammalian PCAM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCAM-1 expression and/or production and activity of PCAM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.Type: ApplicationFiled: March 21, 2001Publication date: April 11, 2002Inventors: Mark Stearns, Youji Hu, Min Wang -
Patent number: 6137032Abstract: A xylanase gene, denoted xynC, encoding a novel xylanase (XynC) obtained from the anaerobic fungus Neocallimastix patriciarum is provided. The DNA sequence of the xynC gene is also provided. Transformation of microbial and plant hosts with the xynC gene is described. The xynC gene may be used to design probes for use in hybridization experiments to isolate xylanase genes from other anaerobic fungi. The xynC gene has been used to construct an oleosin-xynC expression construct encoding an oleosin-xylanase fusion protein which retains xylanase activity. Transgenic Brassica napus (canola), transformed with the oleosin-xynC expression construct, expresses the oleosin-xylanase fusion protein which is immobilized in the oil-body membrane of the B. napus seeds. Canola meal, the protein-rich residue left after canola oil is extracted from canola plants, when derived from the transgenic B. napus of the present invention, retains substantial xylanase activity, making it an ideal animal feed supplement.Type: GrantFiled: September 7, 1999Date of Patent: October 24, 2000Assignee: Her Majesty the Queen in right of Canada, as represented by the Department of Agriculture and Agri-Food CanadaInventors: Kuo-Joan Cheng, Leonard Brent Selinger, Jin-Hao Liu, Youji Hu, Cecil Wallace Forsberg, Maurice Martin Moloney
-
Patent number: 5948667Abstract: A xylanase gene, denoted xynC, encoding a novel xylanase (XynC) obtained from the anaerobic fungus Neocallimastix patriciarum is provided. The DNA sequence of the xynC gene is also provided. Transformation of microbial and plant hosts with the xynC gene is described. The xynC gene may be used to design probes for use in hybridization experiments to isolate xylanase genes from other anaerobic fungi. The xynC gene has been used to construct an oleosin-xynC expression construct encoding an oleosin-xylanase fusion protein which retains xylanase activity. Transgenic Brassica napus (canola), transformed with the oleosin-xynC expression construct, expresses the oleosin-xylanase fusion protein which is immobilized in the oil-body membrane of the B. napus seeds. Canola meal, the protein-rich residue left after canola oil is extracted from canola plants, when derived from the transgenic B. napus of the present invention, retains substantial xylanase activity, making it an ideal animal feed supplement.Type: GrantFiled: November 13, 1996Date of Patent: September 7, 1999Assignee: Her Majesty the Queen in Right of Canada, as represented by the Department of Agriculture and Agri-FoodInventors: Kuo-Joan Cheng, Leonard B. Selinger, Jin-Hao Liu, Youji Hu, Cecil Wallace Forsberg, Maurice M. Moloney